One of the ways drug maker Boehringer Ingelheim has touted its anticoagulant Pradaxa to doctors and patients in Alabama and elsewhere is to claim that the drug has a lower risk of causing intracranial hemorrhage, or bleeding inside the skull. Whether or not that is true, many patients have found that a bleeding incident while on Pradaxa can quickly turn dangerous because there is currently no effective antidote doctors can use to stop the bleeding. Many observers call Pradaxa a defective product and several former patients have sued Boehringer Ingelheim for failure to warn them of this side effect.
Because of the lack of antidote, intracranial bleeding incidents in Pradaxa patients can be more dangerous than for those on comparable drugs. That is the conclusion of a recent journal article on the subject.